Boston Scientific Corp. said late Thursday it has agreed to buy privately held Augmenix Inc. for $500 million in cash and up to an additional $100 million for reaching sales milestones.
Augmenix has developed a therapy to reduce side effects related to prostate-cancer radiotherapy. Sales of the therapy are expected to reach $50 million this year and about $90 million in 2019, Boston Scientific said.
The deal is expected to close early in the fourth quarter, subject to customary closing conditions, and to be immaterial to adjusted per-share earnings this year and the next and accretive by 2020.
Shares of Boston Scientific rose 0.2% in the extended session after ending the regular trading day up 0.7%.
By Claudia Assis
Source: MarketWatch
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.